Contemporary survival in metastatic bladder cancer patients: A population-based study.
SEER
UCUB
metastatic disease
overall survival
systemic therapy
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
revised:
29
05
2024
received:
04
03
2024
accepted:
12
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
The overall survival (OS) improvement after the advent of several novel systemic therapies, designed for treatment of metastatic urothelial carcinoma of the urinary bladder (mUCUB), is not conclusively studied in either contemporary UCUB patients and/or non-UCUB patients. Within the Surveillance, Epidemiology, and End Results database, contemporary (2017-2020) and historical (2000-2016) systemic therapy-exposed metastatic UCUB and, subsequently, non-UCUB patients were identified. Separate Kaplan-Meier and multivariable Cox regression (CRM) analyses first addressed OS in mUCUB and, subsequently, in metastatic non-UCUB (mn-UCUB). Of 3443 systemic therapy-exposed patients, 2725 (79%) harbored mUCUB versus 709 (21%) harbored mn-UCUB. Of 2725 mUCUB patients, 582 (21%) were contemporary (2017-2020) versus 2143 (79%) were historical (2000-2016). In mUCUB, median OS was 11 months in contemporary versus 8 months in historical patients (Δ = 3 months; p < .0001). After multivariable CRM, contemporary membership status (2017-2020) independently predicted lower overall mortality (OM; hazard ratio [HR] = 0.68, 95% confidence interval [CI] = 0.60-0.76; p < .001). Of 709 mn-UCUB patients, 167 (24%) were contemporary (2017-2020) and 542 (76%) were historical (2000-2016). In mn-UCUB, median OS was 8 months in contemporary versus 7 months in historical patients (Δ = 1 month; p = .034). After multivariable CRM, contemporary membership status (2017-2020) was associated with HR of 0.81 (95% CI = 0.66-1.01; p = .06). In conclusion, contemporary systemic therapy-exposed metastatic patients exhibited better OS in UCUB. However, the magnitude of survival benefit was threefold higher in mUCUB and approximated the survival benefits recorded in prospective randomized trials of novel systemic therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 UICC.
Références
EAU Guidelines on MIBC – Introduction – Uroweb. Uroweb – European Association of Urology; n.d. Accessed July 5, 2022. https://uroweb.org/guidelines/muscle‐invasive‐and‐metastatic‐bladder‐cancer
Powles T, Durán I, van derHeijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum‐treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open‐label, phase 3 randomised controlled trial. Lancet. 2018;391:748‐757. doi:10.1016/S0140‐6736(17)33297‐X
Bellmunt J, deWit R, Vaughn DJ, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015‐1026. doi:10.1056/NEJMoa1613683
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours. Eur Urol. 2016;70:106‐119. doi:10.1016/j.eururo.2016.02.028
O'Sullivan B, Brierley J, Byrd D, et al. The TNM classification of malignant tumours—towards common understanding and reasonable expectations. Lancet Oncol. 2017;18:849‐851. doi:10.1016/S1470‐2045(17)30438‐2
Deuker M, Martin T, Stolzenbach F, et al. Bladder cancer: a comparison between non‐urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer. 2021;19:60‐68.e1. doi:10.1016/j.clgc.2020.07.011
deAngelis M, Baudo A, Siech C, et al. Trimodal therapy effect on survival in urothelial vs non‐urothelial bladder cancer. BJU Int. 2024. doi:10.1111/bju.16333
Yates DR, Rouprêt M. Comparing how significantly the pharmacological treatment of genitourinary cancer in a non‐curative setting affects endpoints of survival or response. World J Urol. 2013;31:117‐125. doi:10.1007/s00345‐011‐0798‐5
Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol. 2003;4:489‐497. doi:10.1016/s1470‐2045(03)01168‐9
Flaig TW, Spiess PE, Abern M, et al. NCCN guidelines® insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw. 2022;20:866‐878. doi:10.6004/jnccn.2022.0041
Witjes JA, Babjuk M, Bellmunt J, et al. EAU‐ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU‐ESMO guidelines committees. Eur Urol. 2020;77:223‐250. doi:10.1016/j.eururo.2019.09.035
Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract. 2014;10:e335‐e341. doi:10.1200/JOP.2014.001457
Sorce G, Chierigo F, Flammia RS, et al. Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. Urol Oncol. 2022;40:380.e19‐380.e27. doi:10.1016/j.urolonc.2022.03.014
Veskimäe E, Espinos EL, Bruins HM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle‐invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol. 2019;2:625‐642. doi:10.1016/j.euo.2019.09.003
List of SEER Registries—About SEER. SEER; n.d. Accessed February 1, 2024. https://seer.cancer.gov/registries/list.html
McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021;127:840‐849. doi:10.1002/cncr.33328
Sorce G, Hoeh B, Hohenhorst L, et al. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. World J Urol. 2022;40:2971‐2978. doi:10.1007/s00345‐022‐04183‐0
Tappero S, Piccinelli M, Barletta F, et al. Effect of inguinal lymph node dissection in lymph node negative patients with squamous cell carcinoma of the penis. World J Urol. 2023;41:119‐125. doi:10.1007/s00345‐022‐04184‐z
Siefker‐Radtke AO, Dinney CP, Shen Y, et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013;119:540‐547. doi:10.1002/cncr.27751